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A N U S C R I P T p=0.0241), and interventricular septum hypertrophy (69.2% vs. 0%; p<0001) and less frequently sensory dissociation (12% vs. 74%; p< 0.0001). Also, LO-V30M tended to have more severe mean Neurologic Composite Score (101 vs. 70 pts.; p=0.1136).
Conclusions: LO-V30M ATTRv-PN is not unusual in Brazil, tending to be more difficult to diagnose and present with a more severe phenotype, with more large nerve fibers and cardiac involvement than EO-V30M.
Trial Registration: ClinicalTrials.gov: NCT00628745 Keywords:
familial amyloid polyneuropathy, hereditary transthyretin amyloidosis, polyneuropathy, late-onset ATTRv-PN, early-onset ATTRv-PN.
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ATTRv-PN Hereditary Transthyretin Amyloidosis with Polyneuropathy
EO-V30M
Early-onset Val30Met Transthyretin Amyloidosis (V30M) mutation is the most common mutation in the transthyretin gene worldwide, and the classical V30M ATTRv-PN phenotype is of a small-fiber predominant neuropathy with onset in third or fourth decade (1) . A late-onset form of V30M ATTRv-PN in which symptoms manifest in the sixth decade or later has been reported in several countries, and seems to be the most common form outside endemic regions (2) (3) (4) (5) (6) . Late-onset
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A N U S C R I P T V30M ATTRv-PN affects both large and small sensory fibers and has few autonomic symptoms and more severe motor and cardiac involvement than early-onset disease (7, 8) . Despite being well characterized in other parts of the world, late-onset V30M ATTRv-PN is still poorly characterized in Brazil.
In Brazil, the ATTRv-PN mean age at symptom onset (AO) is 32.5 years; 91.9% have V30M mutation; 90.6% have positive family history (9); and there is an estimated penetrance of 83% at 60 years old (10) . These numbers are very similar to endemic regions in Japan and Portugal (3, 11, 12) . Brazil was colonized by Portugal and is estimated to have more than 25 million Portuguese descendants. In a previous study, we showed that 96.1% of our patients had Portuguese ascendance and only 9% had late-onset ATTRv-PN (13) . However, the number of late-onset cases diagnosed at our center increases every year.
In this study, we characterized demographic and clinical manifestations of late-onset Val30Met ATTRv-PN patients from the Brazilian National Amyloid Referral Center (CEPARM).
Material and Methods
Demographic and clinical data at the time of enrollment were extracted from the ongoing, multinational, longitudinal, observational Transthyretin Amyloidosis Outcomes Survey (THAOS) 7 , with a cut-off date of January 30, 2017. All symptomatic Val30Met
ATTR-PN subjects in Brazil (our center is the only Brazilian site participating in THAOS)
were included in the analysis and divided into two groups: Late-onset (LO-V30M), subjects with symptom onset at age ≥50 years, and Early-onset (EO-V30M), subjects with symptom onset at age <50 years. Descriptive analyses of patients' demographic information, medical histories, and clinical assessments at enrollment were performed.
Misdiagnosis was defined as the last diagnosis received before the diagnosis of ATTRv-PN. Symptoms were categorized in symptoms of motor neuropathy, sensory neuropathy, autonomic neuropathy, gastrointestinal disorders, and cardiac disorder (supplemental table) . In addition, symptoms of muscle weakness, imbalance, and 
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Data are presented as mean ± standard deviation and percentages unless otherwise noted. Differences were assessed using a chi-square analysis for dichotomous variables and student's t-test for continuous variables. Tests were two-sided and p ≤ 0.05 was considered statistically significant. Statistical analyses were performed using SAS ver 9.4.
Results
Study demographic
Of 162 Brazilian subjects enrolled in THAOS, 148 had the Val30Met mutation, of which 96 were symptomatic and were included in this analysis ( was a trend for more severe neurologic impairment in the LO-V30M group (figure 2).
Cardiac involvement
Abnormal ECG occurred more frequently in LO-V30M patients (88.9% vs. 59.4%; p=0.0241), and interventricular septum hypertrophy on ECHO was found only in LO-V30M patients (69.2% vs. 0%; p <0.0001) (figure 2). Only 22% (2/9) LO-V30M patients with cardiomyopathy had symptomatic heart failure. Interventricular septum thickness, posterior wall thickness and left atrial size were higher in the LO-V30M group (p<0.0001) but ejection fraction and left ventricular internal dimension in diastole were not different between groups (table 3) .
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Discussion
For decades, ATTRv-PN was known as small fiber predominant neuropathy with severe autonomic involvement, strong positive family history, and onset at third or fourth decades (11, 17, 18) . However, late-onset cases have emerged as the most common phenotype outside endemic areas. The change in this paradigm is crucial, as probably the most common presentation of ATTRv-PN worldwide is of a length-dependent axonal peripheral neuropathy with pan-modality sensation loss (15) . As ATTRv-PN is a treatable disease (19) , physicians should be aware of clues and red-flags for ATTR-PN in progressive undiagnosed peripheral neuropathies (19, 20) . Differences in the clinical phenotype of early and late-onset Val30Met ATTR-PN have been described in Japan and Portugal, but little was known about these differences in Brazil before our study.
We found that 26% of V30M ATTRv-PN patients from our referral center registered in THAOS are late-onset cases. Brazilian LO-V30M patients have less autonomic and small sensory nerve fiber involvement than EO-V30M, and more large-sensory nerve fiber and motor involvement. Also, we found a trend for more severe neurological impairment compared to the early-onset group and the late-onset cases were more disabled at enrolment. The high rate of misdiagnosis and the huge delay in the diagnosis are worrisome and reflect the challenge in diagnosing late-onset ATTR-PN in Brazil. In the LO-V30M group, CIDP was the most common misdiagnosis, similarly to previous studies (21) (22) (23) . Our study showed that probably one important clue is the cardiac involvement in late-onset cases. We found interventricular septum hypertrophy
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in almost 70% and an abnormal ECG in almost 90% of LO-V30M patients. Interestingly, 78% of the LO-V30M patients with cardiomyopathy did not have symptoms of heart failure. Detection of subclinical cardiomyopathy in old adults and elderlies with progressive polyneuropathies of uncertain etiology should raise the possibility of ATTRv (22) .
Similar neurologic differences between early and late-onset V30M ATTRv-PN patients were encountered in Japan and Portugal (2, 3, 24) . Interestingly, Brazil, Japan, and Portugal appear to share the same origin of the V30M mutation (25, 26) , which came from Portugal probably during the time of the "Age of Discoveries" in the 16th century (27) . The phenotype of our LO-V30M is also similar to LO-V30M patients reported in non-endemic regions in other parts of the world (15, 28, 29) . The reason why V30M is the most common mutation worldwide is not only because of "the travels of genes" in the 16 th century but also probably due to de novo mutations, as there is an CpG dinucleotide sequence in the Val codon at position 30, which is a hotspot for mutations in the human genome (27) . Although it is unknown why LO-V30M has more severe neurologic and cardiologic involvement than do EO-V30M, different patterns of amyloid deposition and sensory nerve fiber involvement have been reported in these two groups.
In V30M ATTRv patients amyloid fibril composition seems to be related to age of symptom onset (30, 31) . In EO-V30M patients fibrils are essentially composed of fulllength TTR, are strongly congophilic, and disposed in parallel. In contrast, amyloid fibrils in LO-V30M patients are usually fragmented, weakly congophilic, and disposed haphazardly, like wild-type ATTR amyloid fibrils (31) (32) (33) . Nerve biopsy studies have shown predominant loss of small sensory fibers in EO-V30M patients and more severe fiber loss in LO-V30M, with variable size distribution (34) . An electron microscopy study showed more blood-nerve-barrier impairment in LO-V30M patients and more prominent amyloid deposits and involvement of small sensory nerve fibers in EO-V30M (35) .
These pathological differences may explain the worse response to liver transplant (36) or TTR stabilizers (37) in LO-V30M patients. Recently, an ultrastructural study done on
a Brazilian V30M ATTRv-PN patient's nerve biopsy showed same very long TTR fibrils that have been shown in Japanese early-onset cases (38) .
The reason why patients with Val30Met ATTR-PN have different ages of symptoms onset is still unclear. Initially, environmental factors were hypothesized but the most important factors are likely genetic (12) . Single-nucleotide haplotypes polymorphisms in the untranslated region of the TTR gene (39), variants in the RBP4 and AR genes (40) and mitochondrial polymorphisms (41) have been found to modulate age at onset in V30M ATTR-PN. Recently, the Mitochondrial DNA copy number has been proposed as a potential mechanism for earlier disease onset and anticipation (42) . These mechanisms may also play a role in the different clinical phenotypes encountered in EO and LO-V30M patients.
Our study has some limitations. First, this is a retrospective analysis from our National Amyloid Referral Center, the only Brazilian center in the THAOS registry, which is located in a presumptively endemic region which may not reflect the same characteristics of the rest of the country. Second, we were not able to sort the patients by region of birth because the THAOS registry does not collect this information.
However, a previous study showed that 77% of our patients are from Rio de Janeiro [12] . Third, there is no epidemiological study to define endemic and non-endemic regions in Brazil.
Conclusions
The late-onset V30M ATTRv-PN is not unusual in the Brazilian population and while it presents with a more severe phenotype than early-onset ATTRv-PN, it is more frequently misdiagnosed, and delays in diagnosis are more common. Brazilian LO-V30M ATTRv-PN subjects tend to be more likely to suffer from more severe neurologic and cardiac impairments, but are less likely to experience autonomic symptoms. Lateonset subjects presented with similar impairment of both small and large fibers compared to early-onset subjects who presented with mainly small fiber neuropathy 
Highlights
 Late-onset V30M ATTRv is not unusual in the Brazilian population  LO-V30M presents with more severe neurologic and cardiac impairments than EO-V30M.  Misdiagnosis and delays in diagnosis are more common in LO-V30M  LO-V30M sensation loss has similar impairment of small and large sensory fibers  Brazilian LO-V30M phenotype is similar to LO-V30M from other parts of the world
